Inspire Medical Systems (NYSE:INSP) Releases Earnings Results, Beats Estimates By $0.38 EPS

Inspire Medical Systems (NYSE:INSP) announced its earnings results on Monday. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38, FiscalAI reports. The business had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.Inspire Medical Systems’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.45 EPS. Inspire Medical Systems updated its FY 2026 guidance to 1.050-1.450 EPS.

Here are the key takeaways from Inspire Medical Systems’ conference call:

• Second-quarter revenue fell 7.6% to $200.6 million as coding and reimbursement disruptions, including lower prior authorizations, weighed on procedure volume. Management estimated the quarter’s revenue was reduced by approximately $40 million by these issues.
• Inspire raised its full-year 2026 outlook to revenue of $835 million–$875 million, adjusted operating margin of 4%–6%, and adjusted diluted EPS of $1.05–$1.45, citing better-than-expected second-quarter profitability and improving reimbursement trends.
• Coding clarity is improving as C-codes are now in place, while CMS has proposed 2027 facility reimbursement increases of approximately 12% for hospitals and 15% for ASCs. However, final rates are not expected until November, and physician reimbursement is proposed to decline about 4%.
• Project Horizon is expected to create approximately $30 million of annualized investment capacity for patient access, education, prior-authorization support, and post-implant engagement, with the company expecting the greatest growth benefit in 2027 and beyond.
• Project Horizon will generate $20 million–$25 million of pre-tax restructuring charges, with roughly 90% expected in the third quarter, while third-quarter revenue is forecast to decline 8%–10% year over year and adjusted operating income is expected to be approximately breakeven.

Inspire Medical Systems Stock Up 4.0%

NYSE:INSP opened at $52.22 on Tuesday. Inspire Medical Systems has a 12-month low of $38.91 and a 12-month high of $147.03. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of 11.63, a P/E/G ratio of 5.08 and a beta of 0.70. The stock’s 50 day moving average price is $46.15 and its two-hundred day moving average price is $55.17.

Wall Street Analysts Forecast Growth

INSP has been the subject of a number of recent research reports. Truist Financial upped their price target on Inspire Medical Systems from $50.00 to $54.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Summit Redstone set a $39.00 price objective on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Wells Fargo & Company cut their price objective on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 5th. Robert W. Baird reduced their target price on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating for the company in a report on Tuesday, May 5th. Finally, Royal Bank Of Canada downgraded shares of Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a research report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $73.28.

Inspire Medical Systems News Summary

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates. Inspire reported adjusted earnings of $0.14 per share, compared with the consensus estimate of a $0.24 loss, while revenue of $200.6 million exceeded expectations of approximately $194.7 million. Inspire Medical Systems Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Full-year EPS guidance was raised above Wall Street expectations. Inspire now expects 2026 earnings of $1.05 to $1.45 per share, versus consensus of approximately $0.91. Revenue guidance of $835 million to $875 million brackets the $848.9 million analyst estimate. Inspire Medical Systems Announces Q2 Results and Raised Guidance
• Positive Sentiment: Management presented a strategic growth plan. The earnings release and conference call emphasized initiatives intended to support future adoption and expansion, giving investors a more constructive outlook for the company’s obstructive sleep apnea treatment business. Inspire Medical Systems Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Growth remains mixed. Quarterly revenue declined 7.6% from the prior year, and EPS fell from $0.45 to $0.14, although both results were better than analysts expected. Investors are therefore likely to focus on whether the new growth initiatives can restore sustained revenue growth.
• Negative Sentiment: The outlook still reflects execution risk. The revenue guidance range is relatively broad, and the midpoint is only modestly above current consensus, leaving the stock dependent on successful commercialization and broader procedure adoption.

Hedge Funds Weigh In On Inspire Medical Systems

Institutional investors and hedge funds have recently modified their holdings of the stock. Smartleaf Asset Management LLC boosted its holdings in shares of Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after buying an additional 205 shares during the period. Daiwa Securities Group Inc. grew its stake in Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after buying an additional 130 shares during the last quarter. Larson Financial Group LLC raised its holdings in Inspire Medical Systems by 21,266.7% in the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after acquiring an additional 638 shares during the period. Quarry LP raised its holdings in Inspire Medical Systems by 695.1% in the 4th quarter. Quarry LP now owns 644 shares of the company’s stock valued at $59,000 after acquiring an additional 563 shares during the period. Finally, Parallel Advisors LLC raised its holdings in Inspire Medical Systems by 349.7% in the 4th quarter. Parallel Advisors LLC now owns 715 shares of the company’s stock valued at $66,000 after acquiring an additional 556 shares during the period. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.